Navigation Links
CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year
Date:2/3/2009

CVS Caremark Proactive Pharmacy Care approach designed to help improve medication adherence to positively impact outcomes and manage costs

WOONSOCKET, R.I., Feb. 3 /PRNewswire/ -- A study released today by CVS Caremark (NYSE: CVS) found that nearly half of patients hospitalized for heart failure may not be adherent to recommended drug therapies, significantly increasing their risk for subsequent hospitalization within 12 months. The study found that among those patients who were non-adherent to drug therapy, average subsequent hospitalizations per patient in a 12 month period (1.1 re-hospitalizations) were almost twice that of adherent patients (0.6 re-hospitalizations).

"The ongoing challenge of medication non-adherence for patients with heart conditions is well known and, as we see with many chronic conditions, medication adherence for heart failure patients is a significant driver of both long term clinical outcomes and cost impact," said Troyen A. Brennan, M.D., M.P.H., Executive Vice President and Chief Medical Officer, CVS Caremark. "To address this issue, CVS Caremark provides our PBM clients with adherence to drug therapy programs that proactively engage participants, achieve significant gains in converting patients to necessary therapies, improve medication adherence and maintain participant compliance over the long term."

The study examined adherence to key heart failure medications (ACE/ARBs, beta-blockers and diuretics) over the 12-months following a heart failure-related inpatient hospitalization. Results found that 49.9 percent of patients studied were not optimally adherent to their medications and had a medication possession ratio (MPR) of less than 0.80. Across all patients, 41% were re-hospitalized at least once within the 12-month follow-up period; however, the highest rate of re-
'/>"/>

SOURCE CVS Caremark
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
2. First U.S. Patients Enrolled in the REALISM Continued Access Study
3. Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
4. Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
5. Study of Cannabinoid Medicine for Pain Found Patients Got High, but Effects Not Related to Pain Relief
6. Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain
7. ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
8. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
9. Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
10. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
11. Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , Chief Financial Officer of Neurocrine Biosciences, will be ... New York City . The ... 11:25am ET (8:25am PT).  The presentation will be webcast ... http://www.neurocrine.com .   Listeners are encouraged ...
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Therapeutic Drug Monitoring - ... This report deals with therapeutic drug ... patient care by monitoring drug levels in the ... for improving outcome. TDM is viewed as a ...
(Date:9/2/2015)... MARIETTA, Ga. , Sept. 2, 2015  MiMedx ... regenerative medicine company utilizing human amniotic tissue and ... and therapies for the Wound Care, Surgical, Orthopedic, ... healthcare, today corrected the inaccurate statements published by ... release of September 1, 2015. MTF,s ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2MiMedx Corrects A Second Inaccurate MTF Press Release 2MiMedx Corrects A Second Inaccurate MTF Press Release 3
... Inc., a privately,held biopharmaceutical company that specializes ... ophthalmic,pharmaceuticals, today reported the interim month three ... pharmacokinetic (PK) study of Medidur(TM) FA,which Alimera ... Iluvien(TM),if approved by the U.S. Food and ...
... developing proposals to fund clinical studies for early detection ... ... 25 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ( http://www.biomoda.com ), a ... the Small,Business Innovation Research (SBIR) and Small Business Technology Transfer,(SBTT) seed ...
Cached Medicine Technology:Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study 2Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study 3Small Business Innovation Research Program Awards Grant to Biomoda 2
(Date:9/3/2015)... ... 03, 2015 , ... Doctor Kayode Sotonwa can be counted on ... perspective on internal medicine keeps patients happy and healthy, something that is important to ... the season, but even more so in the fall, when holiday eating and seasonal ...
(Date:9/2/2015)... ... September 03, 2015 , ... Leah ... among the most influential leaders in healthcare, will offer the keynote address at ... place October 15-16, 2015, in Palm Harbor, Florida, at the Innisbrook Resort and ...
(Date:9/2/2015)... ... 02, 2015 , ... The CRISPR-Cas9 system introduces double-strand DNA breaks ... nuclease with either a chimeric single guide RNA (sgRNA) or two short RNAs (a ... RNA (sgRNA or crRNA) to create a break in the target DNA that causes ...
(Date:9/2/2015)... ... ... to an article published August 12 by International Business Times, a new bill ... grand juries in cases meant to decide if a police officer used deadly or excessive ... in Ferguson and New York City that absolved police officers of charges in the deaths ...
(Date:9/2/2015)... Lauderdale, FL (PRWEB) , ... September 02, 2015 ... ... for Amgen’s Blincyto® (blinatumomab) – in the news recently following a decision by ... hospitalized Medicare patients – is likely to average approximately $71,000 or roughly 40% ...
Breaking Medicine News(10 mins):Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4
... study to identify the composition of bacterial populations on the ... Skin, which// is the largest organ in our body harbors ... previously. Researchers said that it appears that the skin, is ... quite novel. ,Researchers found evidence for 182 species ...
... during pregnancy could lead to diabetes and cardio vascular ... women. Among them, those who had a high BP ... atherosclerosis than their counterparts who had a normal BP. ... latest issue of ‘Hypertension’ suggests that calcification of the ...
... latest Government data, there is an alarming rise in suicides ... linked to the plummeting sale of// antidepressants. ,This ... also indicated that youth in their late teens resorted to ... Administration had issued a black box warning on the antidepressants ...
... conducted by Robert Wilson of Rush University Medical Centre of Chicago ... Alzheimer’s like// Dementia. People who are single or socially secluded are ... their life. ,According to this study, a group of ... age group of 80 for a period of four years. A ...
... Worldwide describes a lawsuit from CSPI -Center for Science in ... claims of their new drink. ,According to the ... more calories and hence, an aid to calorie ... soft drink is laced with EGCG or epigallocatechin gallate which ...
... pain in the jaw may be a sign of a heart ... Uruguay.// ,The symptoms are however often overlooked, and especially ... tooth or jaw ache without chest pains, the study said. ... were asked to indicate on a body chart where they experienced ...
Cached Medicine News:Health News:Human Skin Harbors Many More Types of Bacteria 2Health News:Human Skin Harbors Many More Types of Bacteria 3Health News:Human Skin Harbors Many More Types of Bacteria 4Health News:Human Skin Harbors Many More Types of Bacteria 5Health News:Support Claims With Science Not Magic, Beverage Owners Warned 2
Detection of Malarial antigen in Human whole blood....
Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria)....
Medicine Products: